Lantheus Entered into an Exclusive License Agreements with POINT Biopharma to Commercialize PNT2002 and PNT2003
Shots:
- Lantheus will get an exclusive right globally to develop & commercialize PNT2002 & PNT2003. For both products, POINT will receive $250M & $10M up front, ~$281M & ~$34.5M in milestones upon achievement of US & ex-US regulatory milestones, ~$275M & ~$1.3B in sales milestones along with royalties of 20% & 15%
- The agreement expands Lantheus' radiopharmaceutical portfolio with 2 late-stage therapeutic candidates and boosts Lantheus' prostate cancer franchise with PNT2002. POINT will lead the commercial production capacity for PNT2002 & PNT2003 and will continue to fund & complete its P-III (SPLASH) trial for PNT2002
- POINT will facilitate the completion of a University Health Network-sponsored study in Canada for PNT2003. Lantheus will prepare & submit regulatory filings in the US
Ref: Globenewswire | Image: Lantheus
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
